These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24904828)

  • 1. Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.
    Berois N; Osinaga E
    Front Oncol; 2014; 4():114. PubMed ID: 24904828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
    Cheung IY; Vickers A; Cheung NK
    Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
    Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
    Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.
    Ho WL; Hsu WM; Huang MC; Kadomatsu K; Nakagawara A
    J Hematol Oncol; 2016 Sep; 9(1):100. PubMed ID: 27686492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of CD11b
    Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN
    Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.
    Berois N; Osinaga E
    Front Oncol; 2014; 4():193. PubMed ID: 25120952
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
    Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
    J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
    van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
    J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
    Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD
    Siebert N; Zumpe M; Jüttner M; Troschke-Meurer S; Lode HN
    Oncoimmunology; 2017; 6(10):e1343775. PubMed ID: 29123953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.
    Rossig C; Kailayangiri S; Jamitzky S; Altvater B
    Front Oncol; 2018; 8():513. PubMed ID: 30483473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
    Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
    J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
    Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
    PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.